Companies › PharmaEngine
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PEP07 Selective Chk1 (Checkpoint Kinase 1) inhibitor | CHEK1 | Phase 1 | Acute Myeloid Leukemia; Advanced Solid Tumor | Dec 2026 |
| PEP08 MTA-cooperative PRMT5 inhibitor | PRMT5 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05659732 | PEP07 | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT05983523 | PEP07 | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2027 |
| NCT06973863 | PEP08 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.